Evidence map›Paper›PMID 37646089›Full record

ArticlemAbs

Mammalian display to secretion switchable libraries for antibody preselection and high throughput functional screening.

Ramona Gaa, Hannah Melina Mayer, Daniela Noack, Kavita Kumari, Ralf Guenther, Shang-Pu Tsai, Qingyong Ji, Achim Doerner

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ramona GaaNBE Technologies, Merck KGaA, Darmstadt, Germany.
Hannah Melina MayerNBE Technologies, Merck KGaA, Darmstadt, Germany.
Daniela NoackNBE Technologies, Merck KGaA, Darmstadt, Germany.
Kavita KumariDiscovery Biology, Syngene International, Bangalore, India.
Ralf GuentherNBE Technologies, Merck KGaA, Darmstadt, Germany.
Shang-Pu TsaiNBE Technologies, EMD Serono, Billerica, MA, USA.
Qingyong JiNBE Technologies, EMD Serono, Billerica, MA, USA.
Achim DoernerNBE Technologies, Merck KGaA, Darmstadt, Germany.ORCID 0000-0002-4741-8039

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, there has been a co-evolution of mammalian libraries and diverse microfluidic approaches for therapeutic antibody hit discovery. Mammalian libraries enable the preservation of full immune repertoires, produce hit candidates in final format and facilitate broad combinatorial bispecific antibody screening, while several available microfluidic methodologies offer opportunities for rapid high-content screens. Here, we report proof-of-concept studies exploring the potential of combining microfluidic technologies with mammalian libraries for antibody discovery. First, antibody secretion, target co-expression and integration of appropriate reporter cell lines enabled the selection of

Indexed as

Antibodies, BispecificAnimalsCell LineMammalsAntibodies, BispecificAntibodiesdisplay secretion switchfunction first screenmammalian librariesmicrofluidics

Identifiers

PMID37646089
PMCPMC10469430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.